Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
Juvenile Diabetes Research Foundation (JDRF)
Humacyte, JDRF to develop biovascular pancreas to treat type 1 diabetes
Humacyte (Nasdaq:HUMA) and JDRF announced today that they entered into a collaboration to develop a biovascular pancreas (BVP). The collaboration aims to advance the development of Humacyte’s BVP product candidate for treating type 1 diabetes. Humacyte designed its BVP to deliver insulin-producing islets using its investigational, tissue-engineered blood vessel. The company calls it the Human […]
JDRF launches Type 1 Diabetes Index simulation tool
JDRF announced today that it launched the Type 1 Diabetes Index (T1D Index) data simulation tool for measuring the impact of T1D around the globe. The tool measures the human and public health impact type 1 diabetes has in every country. JDRF said it addresses wide gaps in data about the incidence and impact of […]
Readout Health wins JDRF grant to evaluate handheld breath ketone monitor
Readout Health announced today that it entered into a sponsored research agreement with Washington University School of Medicine. The agreement with Washington University School of Medicine (St. Louis) includes a two-year, $360,000 research grant from JDRF to test the efficacy of the Biosense handheld breath ketone monitor in persons with type 1 diabetes during usual […]
Aspect Biosystems, JDRF partner to develop bioengineered tissue for type 1 diabetes
Aspect Biosystems announced today that it entered into a partnership with the Juvenile Diabetes Research Foundation (JDRF). The partnership will support Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression. Vancouver, British Columbia-based Aspect said […]
FDA approves ready-to-use liquid glucagon from Xeris
Xeris Pharmaceuticals (NSDQ:XERS) said yesterday that the FDA has approved its Gvoke glucagon injection for the treatment of hypoglycemia. Gvoke is a ready-to-use, room-temperature, stable liquid glucagon designed to treat severe hypoglycemia in pediatric and adult patients with Type 1 diabetes aged two years old or above. Chicago-based Xeris’ Gvoke may be administered with a pre-filled […]
Researchers tout use of closed-loop insulin delivery system
At this year’s meeting of the European Association for the Study of Diabetes, researchers reported that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in people with poorly controlled Type 1 diabetes. The JDRF-funded study included 44 men and 42 women with Type 1 […]
SFC Fluidics lands JDRF support for interoperable insulin patch pump
SFC Fluidics said today that it inked a deal with JDRF to support the development of an insulin patch pump with open-protocol communication features. SFC Fluidics plans to use the two-year funding deal from JDRF to speed up the development of a patch pump that securely connects with other devices, like a continuous glucose monitor […]
JDRF tackles insulin consistency, potency at U.S. pharmacies
JDRF is teaming up with the American Diabetes Association and the Leona M. and Harry B. Helmsley Charitable Trust to support research evaluating the consistency and potency of insulin purchased at retail pharmacies in the U.S. The group called for proposals from analytical laboratories to assess the activity of insulin in vials and cartridges, looking […]
Congress doles out $300m to fund diabetes research
Congress today approved a two-year extension of the Special Diabetes Program, giving the National Institutes of Health $300 million to fund research into new therapies and technologies for people with Type I diabetes. The program, which has historically garnered bipartisan support, was last reauthorized in 2015 when lawmakers budgeted $150 million over two years for […]
